KG Related Analyst Ratings
-
Barclays Maintains an 'Overweight' on Pfizer (PFE); King Acquisition: Good But Not Great
-
UBS Downgrades King Pharma (KG) to Neutral; Goodbye King
-
UBS Downgrades King Pharma (KG) to Neutral
-
Wells Fargo Downgrades King Pharmaceuticals (KG) To Market Perform On Proposed Acquisition By PFE
-
Duncan-Williams Downgrades King Pharmaceuticals (KG) to Hold
-
Collins Stewart Downgrades King Pharmaceuticals (KG) to Neutral
-
Susquehanna Starts King Pharmaceuticals (KG) at Neutral
-
Susquehanna Starts AGN, MRX, WCRX at Positive; FRX at Negative; CEPH, ENDP, KG, SHPGY at Neutral
-
Duncan Williams Starts King Pharma (KG) at Buy with $11 Price Target
-
Credit Agricole Upgrades King Pharmaceuticals (KG) to Buy
-
Buckingham Research Downgrades King Pharmaceuticals (KG) to Neutral
-
Needham & Company Maintains a 'Hold' on King Pharmaceuticals (KG); Though Downside Risks Have Abated, Execution Reservations Will Keep Shares Grounded
-
Goldman Sachs Upgrades King Pharmaceuticals (KG) to Neutral
-
Leerink Swann Says M&A Is One Reason To Get Involved In Biophama (AGN, DNDN, BMRN, HGSI, more...)
-
Caris & Co. Initiates Coverage on King Pharmaceuticals (KG) with an 'Above Average'
-
Goldman Sachs Lowers Estimates and Price Target on King Pharmaceuticals (KG)
-
Needham & Company Maintains a 'Hold' on King Pharma (KG); FDA Ad Com Crushes Acurox, Adding Further Skepticism About Ultimate Approvability
-
BMO Capital Downgrades King Pharmaceuticals (KG) to Underperform
-
Goldman Sachs Upgrades AGN, ENDP; Downgrades ENDP, KG
-
Jefferies & Co Initiates Coverage on King Pharmaceuticals (KG) with a Hold
-
Wedbush Upgrades ZymoGenetics (ZGEN) to Outperform; Believe ZGEN on Track to Meet 2010 Sales Estimates
-
Lazard Starts King Pharma (KG) at Buy
-
Goldman Sachs Raises Price Targets On Specialty Pharmaceutical Stocks On Possible M&A (AGN, MRX, KG)
-
Needham & Co Downgrades King Pharmaceuticals (KG) to Hold
-
Goldman Sachs Downgrades King Pharmaceuticals (KG) to Neutral
-
Bank of America Upgrades King Pharmaceuticals (KG) to Buy
-
Collins Stewart Maintains a 'Buy' on King Pharmaceuticals (KG); Three Key Reasons to Own Shares
-
RBC Initiates Coverage on Several Drug Makers
-
Collins Stewart Initiates Coverage on King Pharma (KG) with a Buy
-
UBS Upgrades King Pharmaceuticals (KG) to Buy
-
Goldman Sachs Added King Pharmaceuticals (KG) to its Conviction Buy List
-
Natixis Bleichroeder Upgrades King Pharmaceuticals (KG) to Buy
-
Wachovia Upgrades King Pharmaceuticals (KG) to Outperform
-
Goldman Sachs Upgrades King Pharmaceuticals (KG) to Buy
-
UBS Initiates Coverage on Several Drug Manufacturers
-
Credit Suisse Upgrades King Pharma (KG) to Neutral
-
Oppenheimer Starts King Pharma (KG) at Perform
-
Goldman Sachs Initiates Coverage on Several Pharmaceutical Companies - CEPH, ENDP, FRX, KG, SEPR & WCRX
-
Cowen & Co Downgrades Alpharma (ALO) to Neutral on Acquisition Offer From King
-
Leerink Swann Upgrades King Pharmaceuticals (KG) to Outperform
-
Cowen & Co Upgrades King Pharmaceuticals (KG) to Outperform
-
Natixis Bleichroeder Upgrades King Pharmaceuticals (KG) to Buy
-
Roth Capital Downgrades Alpharma (ALO) to Hold
-
Goldman Sachs Upgrades King Pharmaceuticals (KG) to Buy
-
Citigroup Downgrades King Pharmaceuticals (KG) to Sell
-
Morgan Stanley downgrades King Pharma (KG) to Equal Weight
-
S&P Equity Research Downgrades King Pharmaceuticals (KG) to Hold
-
Cowen & Co Upgrades King Pharmaceuticals (KG) to Neutral
-
Merrill Lynch downgrades King Pharmaceuticals (KG) to Sell
-
JP Morgan upgrades King Pharma (KG) to Neutral
Back to KG Stock Lookup
